HK1069111A1 - Pharmaceutical composition comprising a 5ht1 receptor agonist. - Google Patents

Pharmaceutical composition comprising a 5ht1 receptor agonist.

Info

Publication number
HK1069111A1
HK1069111A1 HK05101699A HK05101699A HK1069111A1 HK 1069111 A1 HK1069111 A1 HK 1069111A1 HK 05101699 A HK05101699 A HK 05101699A HK 05101699 A HK05101699 A HK 05101699A HK 1069111 A1 HK1069111 A1 HK 1069111A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical composition
receptor agonist
agonist
receptor
pharmaceutical
Prior art date
Application number
HK05101699A
Other languages
English (en)
Inventor
Robert William Baker
Aland David Dow
Simon John Summers
Julian Westrup
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of HK1069111A1 publication Critical patent/HK1069111A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK05101699A 2001-12-05 2005-02-28 Pharmaceutical composition comprising a 5ht1 receptor agonist. HK1069111A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0129117.8A GB0129117D0 (en) 2001-12-05 2001-12-05 Pharmaceutical composition
PCT/EP2002/013715 WO2003047552A2 (en) 2001-12-05 2002-12-04 Pharmaceutical composition comprising a 5ht1 receptor agonist

Publications (1)

Publication Number Publication Date
HK1069111A1 true HK1069111A1 (en) 2005-05-13

Family

ID=9927051

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05101699A HK1069111A1 (en) 2001-12-05 2005-02-28 Pharmaceutical composition comprising a 5ht1 receptor agonist.

Country Status (29)

Country Link
US (1) US20050032867A1 (es)
EP (2) EP1450770B1 (es)
JP (1) JP3699969B2 (es)
KR (1) KR100591237B1 (es)
CN (1) CN1289069C (es)
AR (1) AR037627A1 (es)
AT (1) ATE291900T1 (es)
AU (1) AU2002358602B2 (es)
BR (1) BR0214497A (es)
CA (1) CA2469019C (es)
CO (1) CO5580741A2 (es)
DE (1) DE60203537T2 (es)
ES (1) ES2236608T3 (es)
FI (1) FI20022128A (es)
GB (1) GB0129117D0 (es)
HK (1) HK1069111A1 (es)
HU (1) HU229313B1 (es)
IL (1) IL161997A (es)
IS (1) IS2481B (es)
MX (1) MXPA04005420A (es)
MY (1) MY129314A (es)
NO (1) NO329896B1 (es)
NZ (1) NZ532829A (es)
PL (1) PL194702B1 (es)
PT (1) PT1450770E (es)
RU (1) RU2285526C2 (es)
TW (1) TWI240638B (es)
WO (1) WO2003047552A2 (es)
ZA (1) ZA200403849B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
MXPA05010070A (es) 2003-04-11 2005-11-23 Pfizer Combinacion farmaceutica.
BRPI0410807A (pt) * 2003-06-06 2006-06-27 Glaxo Group Ltd composição farmacêutica, e, método pata tratar um mamìfero sofrendo de ou susceptìvel a condições associadas com dor cefálica
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
EP1750677B1 (en) * 2004-05-28 2017-02-01 Imaginot Pty Ltd. Oral therapeutic compound delivery system
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
US20060105039A1 (en) 2004-10-21 2006-05-18 Jin-Wang Lai Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
EP3263117A1 (en) 2005-11-28 2018-01-03 Imaginot Pty Ltd. Oral therapeutic compound delivery system
CN101431895A (zh) * 2006-05-01 2009-05-13 卡普里康制药公司 新颖的曲坦制剂和制备它们的方法
WO2008039358A2 (en) * 2006-09-30 2008-04-03 Capricorn Pharma Inc. Resin-complex granulation for water-soluble drugs and associated methods
RU2563623C2 (ru) 2009-12-02 2015-09-20 Апталис Фарма Лимитед Микрокапсулы фексофенадина и содержащие их композиции
US11364225B2 (en) 2019-08-21 2022-06-21 Bn Intellectual Properties, Inc. Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468504A (en) * 1990-12-21 1995-11-21 Laboratoires Glaxo S.A. Effervescent pharmaceutical compositions
GB9027827D0 (en) * 1990-12-21 1991-02-13 Glaxo Laboratoires Pharmaceutical compositions
GB9104890D0 (en) * 1991-03-08 1991-04-24 Glaxo Group Ltd Compositions
US5460972A (en) * 1991-04-08 1995-10-24 Research Foundation Of The State University Of New York Ionized magnesium2+ concentrations in biological samples
US6649186B1 (en) * 1996-09-20 2003-11-18 Ethypharm Effervescent granules and methods for their preparation
GB9704524D0 (en) * 1997-03-05 1997-04-23 Smithkline Beecham Plc Composition
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
WO1999043306A1 (en) * 1998-02-26 1999-09-02 Banyu Pharmaceutical Co., Ltd. An orally disintegrating composition and its manufacturing method
US6350470B1 (en) * 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
CA2392810A1 (en) * 1999-12-01 2001-06-07 Natco Pharma Limited A rapid acting freeze dired oral pharmaceutical composition for treating migraine
KR20010107754A (ko) * 2000-05-26 2001-12-07 민경윤 경구투여용 속용정의 제조 방법
US20030008005A1 (en) * 2001-07-05 2003-01-09 R.T. Alamo Ventures, Inc. Sublingual administration of dihydroergotamine for the treatment of migraine

Also Published As

Publication number Publication date
AU2002358602B2 (en) 2005-05-26
NO20025805L (no) 2003-06-06
EP1450770A2 (en) 2004-09-01
EP1527773A1 (en) 2005-05-04
AU2002358602A1 (en) 2003-06-17
HUP0402178A3 (en) 2011-05-30
IL161997A (en) 2005-12-18
US20050032867A1 (en) 2005-02-10
RU2285526C2 (ru) 2006-10-20
WO2003047552A2 (en) 2003-06-12
NO20025805D0 (no) 2002-12-03
IS2481B (is) 2008-12-15
HU229313B1 (en) 2013-10-28
DE60203537T2 (de) 2005-09-15
FI20022128A0 (fi) 2002-12-03
MXPA04005420A (es) 2004-10-11
JP2005515991A (ja) 2005-06-02
HUP0402178A2 (hu) 2005-02-28
PL370669A1 (en) 2005-05-30
JP3699969B2 (ja) 2005-09-28
IS7293A (is) 2004-06-03
NZ532829A (en) 2005-05-27
MY129314A (en) 2007-03-30
CA2469019C (en) 2005-09-13
CN1610539A (zh) 2005-04-27
WO2003047552A3 (en) 2003-09-25
BR0214497A (pt) 2004-10-19
NO329896B1 (no) 2011-01-24
ZA200403849B (en) 2005-10-26
GB0129117D0 (en) 2002-01-23
CO5580741A2 (es) 2005-11-30
FI20022128A (fi) 2003-06-06
ES2236608T3 (es) 2005-07-16
PT1450770E (pt) 2005-08-31
ATE291900T1 (de) 2005-04-15
TWI240638B (en) 2005-10-01
CA2469019A1 (en) 2003-06-12
RU2004120292A (ru) 2005-04-10
EP1450770B1 (en) 2005-03-30
IL161997A0 (en) 2005-11-20
PL194702B1 (pl) 2007-06-29
KR20050044720A (ko) 2005-05-12
CN1289069C (zh) 2006-12-13
KR100591237B1 (ko) 2006-06-19
TW200304384A (en) 2003-10-01
AR037627A1 (es) 2004-11-17
DE60203537D1 (de) 2005-05-04

Similar Documents

Publication Publication Date Title
MXPA03005257A (es) Composiciones frarmaceuticas de un agonista del receptor de nmda.
EG24194A (en) 5ht-a-partial agonist pharmaceutical compositions
HK1069111A1 (en) Pharmaceutical composition comprising a 5ht1 receptor agonist.
AU2001280568A1 (en) Heterocyclic beta-3 adrenergic receptor agonists
IL161578A0 (en) Peroxisome proliferator activated receptor agonists
AU2002365655A1 (en) 5-ht7 receptor antagonists
AU2001273508A1 (en) Heterocyclic beta-3 adrenergic receptor agonists
AU2002351730A1 (en) Glucagon receptor antagonists/inverse agonists
AU2001286409A1 (en) N-methyl-d-aspartate receptor antagonists
HUP0200057A2 (en) Dopamine d1 receptor agonist compounds, pharmaceutical compositions containing them and their use
AU2003280065A1 (en) Bupropion hydrochloride solid dosage forms
ZA200110500B (en) Pharmaceutical composition.
MXPA03007272A (es) Formulacion de medicamento que contiene agonista muscarinico.
AU2002302774A1 (en) Macrophage receptor agonist or antagonist
DK1450770T3 (da) Farmaceutisk præparat, der omfatter en 5HT1-receptoragonist
MXPA03007318A (es) Composicion farmaceutica.
AU2002342940A8 (en) New pharmaceutical compounds
SI1347760T1 (en) Nmda receptor agonist pharmaceutical compositions
ZA200110501B (en) Pharmaceutical composition.
ZA200110499B (en) Pharmaceutical composition.
ZA200402034B (en) A pharmaceutical composition.
GB0201849D0 (en) A�- adenosine receptor agonists
GB0201919D0 (en) A�-Adenosine receptor agonists
AU2002338040A1 (en) Receptor antagonist
ZA200402503B (en) Pharmaceutical composition.

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20221203